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1. Introduction 
Currently, breast cancer is a global public health issue. However, recent progress in 
phenotyping and expression profiling of human cancers have greatly enhanced the 
diagnosis and biological classification of several tumors, in particular breast cancers. Despite 
significant advances in cytotoxic chemotherapy, endocrine therapy and novel targeted 
agents, metastatic breast cancer remains an incurable disease (Ocana et al., 2006; Ocana & 
Pandiella, 2008). The lack of curative potential is partially explained by the heterogeneous 
biology of this disease which exhibits both de novo and acquired resistance to many 
treatment modalities (Ocana & Pandiella, 2008).  
Breast cancers are classified into distinct subtypes using microarray-based gene expression 
signatures identification; these are largely based on their (Estrogen) ER, progesterone (PR), 
and HER2 receptor status (Perou et al., 2000; Sorlie et al., 2001; Sorlie et al., 2006). Subtypes 
were designated Luminal A, which strongly expressed ER and/or PR, but not HER2; Luminal 
B, which were ER, PR and HER2 positive; Basal tumors which were ER, PR, and HER 
negative, preferentially affecting young women and women of African origin, usually of 
high histological grade and more aggressive clinical behavior (Yehiely et al., 2006) .   
Genomic tumor profiling has provided us with important insights to mechanisms of 
tumorigenesis and translational data for clinical advances (Bauer et al.). Relative to some 
cancer types, there is tremendous genomic information available for breast cancers, which 
includes tumor DNA copy number (Adelaide et al., 2007; Bergamaschi et al., 2006; Chin et 
al., 2006; Han et al., 2008; Neve et al., 2006) DNA sequence and mutations (Leary et al., 2008; 
Nikolsky et al., 2008; Shah et al., 2009; Sjoblom et al., 2006; Stephens et al., 2009; Wood et al., 
2007), gene expression and protein profiles(Boyd et al., 2008; Hennessy et al., 2009), as well 
as epigenetics (Andrews et al.; Ruike et al.) and microRNAs  (Iorio et al., 2005a; Mattie et al., 
2006a). 
Promising new targeted agents, such as small molecule tyrosine kinase inhibitors and 
monoclonal antibodies such as trastuzumab, which targets breast cancer cells 
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overexpressing her2neu, are rapidly making their way into general oncology practice in 
high-resource countries. These “smart bombs” of the oncologywill, no doubt, have 
increasing utility either as stand-alone or adjunct drugs in the armamentarium of anti-
neoplastics. However, given the experience to date with cost of these agents, and the 
likelihood that any of these drugs will be off-patent and “genericized” in the coming decade, 
it is presently entirely beyond the reach of low and middle-resource countries to even 
consider their use.  
According to the WHO, a drug may be considered cost-effective if the annual cost per 
quality-adjusted life year saved, or QALY, is no greater than a country’s per capita GDP 
(gross domestic product) ("https://www.cia.gov/library/publications/the-world-
factbook/,").  Although major share of drug development budgets are focused on targeted 
agents, which escalates the cost of the drug. Hence to decrease drug cost, drug activity 
should be improved, and treatment failures need to avoided, to achieve this identification of 
common ‘drugable’ oncogenic mechanisms is an important area to focus research.  
Many strategies have been developed to treat cancer by targeting the cancer cells without 
affecting normal cells. Recent research on gene delivery such as, siRNAs, miRNAs which 
have been proven to control breast cancer tumors can be introduced into breast tissue 
through the use of nanoparticle technology and breast cancer targeting immunoconjugates.  
Hence, in this chapter we will focus mainly translational research on novel formulation that 
contains miRNA or siRNA or immunoconjugate modified to nanoparticles for specific 
delivery to breast cancer tissues.  Thus this chapter will divides into four sub sections, first 
three will be briefing current updates on miRNA, siRNA, immunoconjugates,  relevant to 
breast cancer research ;and the fourth one is  clinical applications on nanoparticles  modified 
with targeting agents to deliver into breast cancer cells.  Hence this book chapter will be an 
unique one to all breast cancer researchers with the following expertise; gene delivery, 
nanotechnology, immunologists, clinicians, and clinical translational scientists. 
2. MicroRNAs  
MicroRNAs (miRNAs) are a family of endogenous, noncoding, small single stranded RNAs 
(21-25 nucleotides) that regulate the gene expression at post-transcriptional levels 
(Venugopal et al., 2009; Yoon et al., 2010). miRNAs bind to the target sequences by partial or 
complete binding to the 3’ untranslated region (UTR) of their target mRNAs, and thereby 
mediate mRNA degradation or translational inhibition, which depends on the degree of 
complementarity between miRNAs and their targets (Carthew, 2006). They appear to 
function via several mechanisms in repressing gene expression and regulating cellular 
activities, such as development (Ambros, 2004), cell proliferation (Zhang et al., 2006), 
differentiation (Esau et al., 2004), apoptosis (Cimmino et al., 2005), glucose metabolism (Poy 
et al., 2004), stress resistance (Dresios et al., 2005), and cancer (Calin et al., 2002). One of the 
miRNAs, which is abundantly expressed in the liver, and appears to affect hepatic function, 
is microRNA-122a (miR-122a)(Krutzfeldt et al., 2005). Using antagomiR-122a, when miR-
122a expression was silenced, there was a 44% decrease in cholesterol synthesis in 
hepatocytes (Krutzfeldt et al., 2005). The mechanism of this effect appears to be that 
inhibition of miR-122a caused the activation of a transcriptional repressor protein involved 
in cholesterol biosynthesis (Krutzfeldt et al., 2005). Another study reported that inhibition of 
miR-122a in the liver caused a marked loss of hepatitis C viral RNAs, and that miR-122a 
may represent a target for antiviral intervention (Jopling et al., 2005). Several miRNAs have 
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been implicated in the process of apoptosis and cell proliferation in non-liver systems 
(Cimmino et al., 2005; Xu et al., 2004). For example, miR-21 has been shown to inhibit 
caspase activation, thereby promoting anti-apoptosis (Chan et al., 2005). miR-15 and miR-16 
were shown to promote apoptosis by interacting with Bcl-2 (Cimmino et al., 2005), and 
down-regulation of miR-27b caused apoptosis (Scott et al., 2006). Another study shows that 
miR-126 increased the growth and proliferation of megakaryocytes (Garzon et al., 2006), and 
that miR-451 enhanced the differentiation of erythroid cells (Rathjen et al., 2006). The 
miRNAs, which are secreted to the blood stream, can be detected and used as diagnostic 
markers, one such example is miR-21 released to the blood stream. It has shown by various 
investigators that several of these miRNAs including miR-21, miR-126 have been shown to 
be involved in the progression of breast cancer.  Anti-cancer therapies are also focused in 
modulating the expression of miRNAs to inhibit cell growth, proliferation and invasion.  
The biogenesis of miRNA occurs in nucleus, like other genes, (Figure 1) and a longer 
primary miRNA is transcribed by RNA polymerase II or III. The primary miRNA is 
processed by the RNAse III endonuclease Drosha and DGCR8 to form stem-loop structure 
 
 
Fig. 1. Schematic diagram of the biogenesis of microRNA in eukaryotic cells. (Reproduced 
with permission from Nature Cell Biology, 2009) 
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of approximately 50 nculeotides long called “precursor miRNA” (pre-miRNA)(Borchert et 
al., 2006; Gregory et al., 2004; Han et al., 2004; Lee et al., 2004). The pre-miRNA is 
transported from the nucleus to the cytoplasm with the help of exportin 5, where this pre-
miRNA will undergo further processing by another RNase III endonuclease, Dicer (Lee et 
al., 2003; Lund et al., 2004). Dicer removes the loop structure of the pre-miRNA to produce 
an imperfect duplex made up of the mature miRNA and a fragment of similar size 
(miRNA*), which is derived from the opposing arm of the pre-miRNA. The miRNA strand 
of the duplex is loaded onto the RNA-induced silencing complex (RISC); the miRNA* gets 
separated from the duplex and is degraded (Lee et al., 2002). 
Regulation of gene expression by miRNAs occurs either by degrading the mRNA or by 
inhibiting the translation of the mRNA. The mechanisms by which the miRNAs inhibit the 
translation depends on the degree of complimentarity between the particular miRNA and 
the target mRNA. If there is a perfect complementarity, the target mRNA sequence is 
degraded and if there is an imperfect complementarity, the translation of the mRNA is 
blocked (Hutvagner & Zamore, 2002). 
These miRNAs can bind to a seed sequence (about 6-8 bases) of the approximately 22 
nucleotides aligns perfectly with the target mRNA’s 3’ untranslated region and can bind 
more than one target sequence. Hence, finding the target sequences for these miRNAs has 
been difficult for researchers. Using bioinformatic approaches, we can identify the putative 
targets of these miRNAs, but one needs to conduct confirmatory laboratory experiments to 
establish the target genes. 
2.1 miRNA and cancer 
In most of the cancers, expression of miRNA is generally decreased, as most of them may act 
as tumor suppressors (Lu et al., 2005). Furthermore, poorly differentiated tumors have lower 
miRNA levels compared to more differentiated tumors, indicating that global changes in 
miRNA expression may indicate the degree of cellular differentiation. Recently it has been 
shown that several miRNAs were expressed at lower levels in human tumor-derived cell 
lines compared to the corresponding tissue (Gaur et al., 2007). Another study has also 
shown that a loss in the expression of miRNA in cancer resulted in tumorigenesis (Kumar et 
al., 2007). When drosha and dicer were knocked down, which are needed for the miRNA 
biogenesis, there was a complete loss of miRNA expression. When these cells were injected 
in nude mice, they formed accelerated growth with increased invasive properties. These 
results suggest that the loss of miRNA expression enhances tumorigenesis.  
2.2 miRNA in breast cancer  
Several studies have been conducted in the recent past on profiling miRNAs and found that 
several of them were aberrantly expressed in breast cancer tissues. Although several of the 
functions of these miRNAs were studied, still an array of experiments needs to be 
conducted for utilizing them as diagnostic markers or therapeutic agents. In addition, tumor 
metastasis may be promoted by enhanced expression of prooncogenic/prometastatic 
and/or downregulation of antioncogenic/antimetastatic miRNAs.  
Several miRNAs have shown to be deregulated in breast cancer, suggesting that these 
miRNAs may modulate oncogenesis (Iorio et al., 2005b; Lu et al., 2005; Yu et al., 2010). Lu et 
al. (Lu et al., 2005) had reported that miRNA expression is downregulated in tumors, 
including breast cancer. Several miRNAs, such as miR-10b, miR-125b and miR-145 were 
down regulated, while miR-21 and miR-155 were up regulated, suggesting that these 
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miRNAs may play an important role as either tumor suppressor genes or oncogenes (Iorio 
et al., 2005b). A recent study has shown that miR-7, miR-128a, miR-210 and miR-51-3p were 
involved in breast cancer progression (Foekens et al., 2008). Upregulation of miR-373 and 
miR-520c promotes metastasis by inhibiting CD44 expression (Huang et al., 2008). Ma et al. 
(Ma et al., 2007) showed that a transcription factor, twist1, is involved in the upregulation of 
miR-10b. Suppression of miR-21 led to an increase in apoptosis and inhibition of bcl-2 (Si et 
al., 2007). miR-21 also has been shown to inhibit tropomyosin 1, which plays an important 
role in antioncogenic function including binding microfilaments and regulating cytosekleton 
miRNAs (Zhu et al., 2007). miR-27a is reported to inhibit the transcription factor 
ZBTB10/RINZF, which is a putative suppressor of specificity protein (Sp) (Mertens-Talcott 
et al., 2007). Overexpression of Sp by miR-27a contributes to the increased expression of Sp-
dependent survival and angiogenic genes, including survivin, vascular endothelial growth 
factor (VEGF) and VEGF receptor 1. miR-175p is inhibited in breast cancer and it regulates 
AIB1 (Amplified in Breast Cancer-1 protein) (Hossain et al., 2006). AIB1 is a coactivator for 
nuclear receptors, such as estrogen receptor, and is overexpressed in breast cancer. Both miR-
125a and miR-125b are down-regulated in breast cancer and these miRNAs suppress the HER2 
and HER3, the two tyrosine kinase receptors frequently deregulated in breast cancer (Scott et 
al., 2007). miR-206 has been found to target the 3’UTR of the estrogen receptor- protein, 
leading to an inverse correlation between miR-206 concentration and estrogen receptor- 
status (Adams et al., 2007; Kondo et al., 2008). Some of the key miRNAs, which are shown to 
be involved in modulating tumor growth and metastasis, is described below. 
2.3 Oncogenic miRNAs 
miR-21 
There have been several studies showing that miR-21 is consistently overexpressed in many 
tumors, including breast cancer (Iorio et al., 2005b; Volinia et al., 2006). It also has been 
shown that miR-21 was highly upregulated in breast tumors compared to the matched 
normal breast tissues among 157 human miRNAs analyzed by real-time RT-PCR arrays (Si 
et al., 2007), suggesting that miR-21 may function as an oncomiR. In the later study the 
authors have also shown that knocking down miR-21 resulted in a marginal decrease in cell 
survival (25% decrease), and the authors found that this growth inhibition increased when 
the transfected MCF-7 cells were treated with the anticancer drug topotecan, suggesting that 
suppression of miR-21 can sensitize tumor cells to anticancer agents. The target prediction 
using bioinformatics approaches followed by experimental validation showed that 
tropomyosin 1 (TPM1), which is known to be downregulated in breast cancer epithelial cell 
lines, was a target of miR-21 (Zhu et al., 2007). miR-21 has also been shown to inhibit the 
expression of the tumor suppressor PDCD4 (programmed cell death-4) (Frankel et al., 2008). 
Another important target of miR-21 is the tumor suppressor gene phosphatase and tensin 
homolog (PTEN) (Qi et al., 2009). These genes were shown to reduce invasiveness of a 
metastatic breast cancer cell line. These findings further establish miR-21 as an oncogenic 
miRNA and suggest that miR-21 has a role not only in tumor growth but also in invasion 
and tumor metastasis by targeting multiple anti-metastatic genes. 
miR-155 
MiRNA microarray has shown that miR-155 is over-expressed in a number of human 
malignancies, including breast cancer (Iorio et al., 2005b; Volinia et al., 2006). A recent study 
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has shown that miR-155 is upregulated in normal mouse mammary gland epithelial cells 
(NMuMG cells) by the TGF-┚/Smad4 pathway and mediates TGF-┚-induced EMT and cell 
invasion (Kong et al., 2008). miR-155 directly inhibits the expression of RhoA, a gene that 
regulates many cellular processes, including cell adhesion, motility, and polarity, and is an 
important modulator of cell junction formation and stability. It also has been shown that 
miR-155 is highly expressed in invasive tumors but not in noninvasive cancer tissues.  
miR-10b 
miR-10b was found to influence the metastatsis of human cancer cells (Ma et al., 2007). 
Unlike miR-155, which is overexpressed in many breast tumors, miR-10b was highly 
expressed only in metastatic cancer cells and was found to promote cell migration and 
invasion in vitro and initiate tumor invasion and metastasis in vivo. miR-10b expression is 
shown to be regulated by a transcription factor Twist, and miR-10b inhibits the translation 
of the transcription factor homeobox D10 (HOXD10), resulting in a cascade of cellular 
alterations that include expression of the prometastatic gene RHOC (ras homologue gene 
family member C), a gene that promotes cancer cell migration and invasion. 
miR-373/520c family 
miRNAs of the miR-373/520c family were identified (Kato et al., 2009) as prometastatic 
using a forward genetic screen involving overexpression of almost 450 miRNAs in a 
nonmetastatic human breast cancer cell line (MCF-7 cells). MCF-7 cells were transduced 
with these miRNAs and subjected to a trans-well cell migration assay to identify miRNAs 
that stimulate cell migration. The authors found that miR-373 and miR-520c promoted 
cancer cell migration and invasion in vitro and in vivo. It has been shown that the 
downregulation of CD44 (a metastasis repressor) was found when miR-373 or miR-520c 
were overexpressed in MCF-7 cells.  
2.4 Tumor suppressor miRNAs 
miR-206 
Using miRNA microarrays it was found that miR-206 is involved in suppressing breast 
cancer cells (Iorio et al., 2005b). miR-206 was upregulated in estrogen receptor (ER)┙-
negative breast cancers, suggesting a role of miR-206 in regulation of the estrogen receptor 
gene ERα (ESR1). Indeed, miR-206 was recently shown to inhibit the expression of ESR1 
mRNA through two binding sites in the ESR1 3' UTR (Kumar et al., 2007). The latter study 
also showed that miR-206 expression was strongly repressed by ER┙ agonists, but not by an 
ER┚ agonist or progesterone, suggesting the existence of a feedback loop. Another study 
had shown that miR-206 expression decreased in ER┙-positive human breast cancer tissues 
and that miR-206 suppresses ESR1 expression and inhibits growth of MCF7 breast cancer 
cells. In addition to miR-206, the authors found that ESR1 mRNA was a direct target of miR-
18a, miR-18b, miR-193b and miR-302c in breast cancer cells (Leivonen et al., 2009), most of 
which were shown to induce cell cycle arrest and to inhibit estrogen-induced proliferation. 
Bioinformatics approach had revealed that the direct targets of miR-335 are PTPRN2, 
MERTK, TNC and SOX4; among them, TNC (encoding an extracellular matrix component) 
and SOX4 (encoding a transcription factor that is involved in tumorigenesis) were shown to 
be functional targets implicated in metastasis. Restoring miR-206 expression in metastatic 
cells did not influence their proliferation or sensitivity to apoptosis, but altered cellular 
morphology, possibly contributing to a decrease in cell motility that could limit the 
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migration of metastatic cells (Tavazoie et al., 2008). These findings suggest that miR-206 
could be a novel candidate for breast cancer therapy. 
miR-17-5p 
miR-17-5p, also known as miR-91, is located on chromosome 13q31, a genomic region that 
undergoes loss of heterozygosity in multiple cancers, including breast cancer (Eiriksdottir et 
al., 1998). The oncogene AIB1 (amplified in breast cancer) is a direct target of miR-17-5p 
(Hossain et al., 2006). The protein encoded by the AIB1 gene is a steroid receptor co-activator 
that enhances the transcriptional activity of ERα, E2F1 (which is also directly regulated by 
miR-17-5p) and other transcription factor genes. Downregulation of AIB1 by miR-17-5p 
results in the suppression of estrogen-stimulated proliferation and estrogen/ER-
independent breast cancer cell proliferation (Hossain et al., 2006). In breast cancer cells, the 
gene cyclin D1 (CCND1), which is overexpressed in approximately 50% of human cancers, 
was recently identified as a direct target of miR-17-5p (Yu et al., 2008). miR-17-5p inhibits 
the proliferation of breast cancer cells by suppressing cyclin D1 protein synthesis. miR-125a 
and miR-125b 
miR-125a and miR-125b are downregulated in HER2-amplified and HER2-overexpressing 
breast cancers (Mattie et al., 2006b). These two miRNAs are potential tumor suppressors and 
their overexpression in SKBR3 cells (a HER2-dependent human breast cancer cell line) 
suppresses HER2 and HER3 mRNA and protein levels, leading to a reduction in anchorage-
dependent growth, cell motility, and invasiveness (Scott et al., 2007). However, this 
influence was subtle in non-transformed HER2-independent breast cancer cells (MCF10A). 
miR-200 family 
Overexpression of miR-200 induced epithelial differentiation in undifferentiated breast 
cancer cells (MDA-MB231) whereas antagonizing it induced an EMT phenotype in the 
colorectal cancer cell line HCT116. ZEB1 and ZEB2 were again detected as targets of the 
miR-200 family members. These and other recent reports on the miR-200 family (Hurteau et 
al., 2009; Korpal et al., 2008) add important miRNAs to the growing list of tumor-associated 
miRNAs. Furthermore, a recent study showed that the expression of the miR-200 family was 
decreased by Akt2, suggesting that, in many cases, breast cancer metastasis may be under 
the control of the Akt-miR-200-E-cadherin pathway (Iliopoulos et al., 2009). Interestingly, a 
recent study showed that expression of miR-200 unexpectedly enhanced macroscopic 
metastases in mouse breast cancer cell lines (Dykxhoorn et al., 2009). Their results suggest 
that, for some tumors, tumor colonization at metastatic sites might be enhanced by 
mesenchymal-to-epithelial transition (MET). MET is a reversible biological process that 
involves the transition from motile, multipolar or spindle-shaped mesenchymal cells to 
planar arrays of polarized cells called epithelia.  Thus the epithelial nature of a tumor would 
be difficult to predict metastatic outcome. Taken together, these studies suggest that 
miRNAs of the miR-200 family play important roles in regulating tumor progression and 
metastasis. 
let-7 family 
let-7 is poorly expressed or deleted in many human cancers. Recent data from both 
hematologic malignancies and solid tumors suggest that each includes minor populations of 
cells that are capable of tumor initiation (Clarke & Fuller, 2006). A recent study compared 
miRNA expression in self-renewing and differentiated cells from breast cancer lines and 
found that the expression of let-7 was strongly reduced in breast tumor initiating cells (BT-
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ICs) and increased with differentiation (Yu et al., 2007). Introducing let-7 in BT-ICs reduced 
their proliferative capacity, their ability to form mammospheres and tumor formation and 
metastasis in vivo. Conversely, knocking down let-7 enhanced self-renewal of non-T-ICs in 
vitro. Known oncogenic targets of let-7, such as H-RAS and HMGA2, were downregulated 
by let-7 overexpression. Silencing H-RAS in a BT-IC-enriched cell line reduced self-renewal 
but had no effect on differentiation, while knocking down HMGA2 enhanced differentiation 
but did not affect self-renewal. Their results suggest that let-7 regulates multiple BT-IC stem 
cell-like properties and that let-7 may offer a unique opportunity to attack tumor stem cells 
using therapeutic RNA. Delivery of the let-7 miRNA to tumors could potentially deplete 
stem cells by inducing cellular differentiation. 
miR-34a 
miR-34a is one of several miRNAs that are downregulated in multiple cancers (Gaur et al., 
2007) and has been shown to be transcriptionally regulated by p53. In the context of breast 
cancer, only one study (Kato et al., 2009) has shown that miR-34a levels were lower in triple 
negative and mesenchymal breast cancer cell lines compared with normal epithelial lines 
and HER-2+ lines. Increasing the levels of miR-34a protected the MDA-MB-231 cells from 
radiation-induced cell death, and downregulating it had the converse effect. These results 
show that miR-34a is necessary for the survival of MDA-MB-231 cells from non-apoptotic 
cell death and suggest that miR-34a may have therapeutic potential in breast cancers, since 
antagonizing miR-34a increases the sensitivity of breast cancer cells towards radiation. 
miR-31 
miR-31 was recently shown to prevent metastasis at multiple steps by inhibiting the 
expression of prometastatic genes (Valastyan et al., 2009). miR-31 is expressed in normal 
breast cells and its abundance was shown to be dependent on the metastatic state of the 
tumor. It is moderately decreased in non-metastatic breast cancer cell lines and is almost 
undetectable in metastatic mouse and human breast cancer cell lines. Importantly, the 
authors demonstrated that introducing miR-31 in metastatic breast cancer cells suppressed 
metastasis-related functions (motility, invasion and resistance to anoikis) in vitro and 
metastasis in vivo. Injecting miR-31 overexpressing cells directly into the circulation 
impeded the ability of the cells to survive and form secondary tumors in the lung, 
suggesting that miR-31 inhibits metastasis at multiple steps of the metastatic cascade. 
Conversely, inhibition of miR-31 function increased invasiveness and promoted metastasis 
in vivo. The targets have been identified for this miRNA is frizzled3 (Fzd3), integrin ┙-5 
(ITGA5), myosin phosphatase-Rho-interacting protein (M-RIP), matrix metallopeptidase 16 
(MMP16), radixin (RDX) and the ras homolog gene family member A (RhoA). Taken 
together, their findings demonstrate that miR-31 may also be an attractive therapeutic target 
for breast cancer as it exerts its antimetastatic effect by targeting multiple prometastatic 
genes of the metastasis cascade. 
3. Nanoparticles in breast cancer translational research 
Nanoparticles (NP) have been widely utilized in biomedical applications; such as drug 
delivery, transfection agents, molecular imaging, and as bioprobes. The size and surface 
area of NP provide unique features to modify various functions using organic/inorganic 
compounds. Thus NPs provide an excellent template for multimodality agents such as 
imaging, tracking, and sensitive detection of biomarkers specific to disease (Medarova et al., 
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2007; Phillips et al., 2008; Sonnichsen et al., 2005; Yang et al., 2007). Several classes of NPs 
have been developed and utilized for various applications. For example, oligonucleotide-
functionalized nanoparticles have been introduced as an effective bioassay tool, referred to 
as a bio-barcode assay, which allows for sensing small biomolecules such as ┚- amyloid 
related to Alzheimer’s disease and small DNA fragments associated with various diseases 
such as human immunodeficiency virus (HIV) (Keating, 2005; Stoeva et al., 2006). 
Furthermore, NPs linked to antibodies have demonstrated selective binding of rare stem 
cells, immune cells and cancer cells presenting specific receptors on the cell surface 
(Pissuwan et al., 2007). Several study reports have been showed that antibodies linked to NP 
can detect or target cells with high specificity (Yang et al., 2007). In our recent study, we 
have used gold nanoparticles (AuNP) of a small size (10 nm) coated with streptavidin (SA) 
for conjugation of molecules to create a nanoimmunogene conjugate (Yoon et al., 2010). This 
conjugates includes an apoptosis-inducing miRNA (miRNA-491), breast cancer targeting 
MAb, and quantum dots to target breast cancer selectively and to induce apoptosis 
(Natarajan et al., 2009). This novel approach of making multifunctional nanoparticles, 
combining NP, miRNA and antibody, will target cell surface receptors, and subsequently 
nanoparticles will enhance the transfection of apoptosis-inducing miRNA into the cell to 
enhance the apoptosis (Figure 2). 
 
 
Fig. 2. Images left to right shows evidence of apoptosis in HBT3477 human breast cancer 
cells treated with miR-491-AuNP 10nm for 24h. The apoptotic effect was analyzed by 
Transmission Electron microscopy to confirm the morphological changes at a cellular level. 
Morphological changes show irregular nuclear contours, smudged chromatin (left panel), 
and focal breakdown of the nuclear membrane (center panel) as well as; marginated and 
clumped chromatin at the periphery (right panel).  
3.1 Targeted nanoparticles 
Nanomaterials or nanoparticles (NPs) are currently, synthesized by various polymers and 
lipids; iron, gold and silica particles. These particles are typically < 200 nm size used for 
drug delivery vehicles that can carry multiple drugs and/or imaging agents. Due to high 
surface-area-to-volume ratio, it is possible to achieve high ligand density on the surface for 
targeting purposes. Further, NPs can also be used to increase local drug concentration by 
carrying the drug within and control-releasing it when bound to the targets.  
Targeted nanoparticles (NPs) conjugates are created by linking to targeting agents such as 
proteins (mainly antibodies and their fragments), nucleic acids (aptamers), or other receptor 
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ligands (peptides, vitamins, and carbohydrates).  These NPs that are chemically conjugated 
with drugs are often considered new chemical entities owing to a distinct pharmacokinetic 
profile from that of the parent drug. 
In spite of variety of novel drug targets and sophisticated chemistries available, only four 
drugs (doxorubicin, camptothecin, paclitaxel, and platinate) and few polymers (N-(2-
hydroxylpropyl)methacrylamide (HPMA) copolymer, poly-L-glutamic acid, poly(ethylene 
glycol) (PEG), and Dextran) have been reported quite often used to develop NP–drug 
conjugates(Duncan, 2006). 
Many polymer based NP–drug conjugates have entered Phase I and II clinical trials and 
these are especially useful for targeting blood vessels in tumors. Examples include anti-
endothelial immunoconjugates, fusion proteins (Arap et al., 1998; Halin et al., 2002; Schraa et 
al., 2002), and caplostatin, the first polymer-angiogenesis inhibitor conjugates (Satchi-
Fainaro et al., 2004).   
3.2 miRNA-NPs 
The key to success of RNA-based therapeutics is to have effective strategies for the delivery 
of siRNA or miRNA in vivo (Hammond, 2006). For example, modification of antisense RNA 
with a cholesteryl functionality results in enhanced stability in the serum, improved cellular 
uptake and inhibition of target mRNA (Krutzfeldt et al., 2005). If the delivery of miRNAs 
through nanoparticles is proven to be an effective breast cancer therapeutic, this could 
revolutionize breast cancer treatment.  In contrast to chemotherapy, targeted miRNA-
nanoplatform is only the tumor would be targeted for treatment, preventing serious side-
effects. Thus delivering siRNA and / or miRNA with nanoparticles simultaneously 
targeting several different oncogenic pathways is definitely an important advantage of the 
current approach. 
Chen et al first developed an approach for co-delivery of siRNA and miRNA using 
liposome-polycation-hyaluronic acid particles with tumor targeting single-chain antibody 
fragment to target murine B16F10 melanoma (Chen et al., 2010). Targeted nanoparticles with 
miR-34a induced apoptosis inhibited survivin expression, in the metastatic tumor and 
reduced tumor load in the lung. This study clearly demonstrated this novel therapeutics 
enhanced the antitumor effect. Similarly in another study by Anand et al demonstrated mir-
132 linked nanoparticles were able target ┙V┚3 integrins to manuplate miRNA levels in the 
endothelium to control pathological neovascularization (Anand et al., 2010). 
Natarajan et al delivered miR491 to induce apoptosis in human breast cancer cells (HT3477) 
using quantum dots, gold nanoparticles, and HBT3477 targeting Mab. The transmission 
electron microscopy (Fig 2) clearly showed the apoptotic effect on cells due to delivery of 
Au-NP-miR491, compared to control cells which were not delivered miR-491.  
3.3 SiRNA-NPs 
Gene silencing using short interfering RNA (siRNA) is an attractive approach to probe gene 
function, and to silence cancer genes in mammalian cells. Recently some success in the 
delivery of siRNA using various methods; here we mainly discuss their delivery through 
non viral vectors using nanoparticles for breast cancer imaging and therapy. Kumar et al 
synthesized (Kumar et al., 2010) a tumor-targeting nanodrug of Iron oxide nanoparticles 
linked to peptide and small interfering RNA (siRNA), (MN-EPPT-siBIRC5) to specifically 
shuttle siRNA to human breast tumors. The nanodrug binds the tumor-specific antigen 
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uMUC-1, which is found in >90% of human breast adenocarcinomas. MN-EPPT-siBIRC5 
consists of superparamagnetic iron oxide nanoparticles [for magnetic resonance imaging 
(MRI)], the dye Cy 5.5 (for near-IR optical imaging), peptides (EPPT) that specifically target 
uMUC-1, and a synthetic siRNA that target the tumor-specific anti apoptotic gene BIRC5. 
Nanodrug uptake by human breast adeno carcinoma cells resulted in a significant down 
regulation of BIRC5. Following i.v. delivery into subcutaneous mouse models of breast 
cancer, the nanodrug showed a preferential tumor uptake, which could be visualized by 
MRI and near-IR optical imaging. Intravenous injection of the agent once a week over 2 
weeks resulted in the induction of considerable levels of necrosis and apoptosis in the 
tumors, translating into a significant decrease in tumor growth rate. This strategy permits 
the simultaneous tumor-specific delivery of siRNA to tumors and the imaging of the 
delivery process.  
Bouclier et al studied suppression (Bouclier et al., 2010) of oestrogen receptor alpha 
(ERalpha) functions by silencing RNAs in association with or not with anti-oestrogens (AEs) 
both in vitro and in breast cancer cell xenografts was assessed. In vitro, a prolonged 
decrease in ERalpha protein expression and an enhanced AE-induced inhibition of ERalpha-
mediated transcription, together with antiproliferative activity, were observed. 
Incorporation of ERalpha-siRNAs in PEGylated nanocapsules (NC) was achieved; and their 
intravenous injections in MCF-7 xenografts, in contrast to scramble siRNA containing NCs, 
lead to decrease in ERalpha protein content and Ki67 labeling in tumour cells. In this study, 
co-injection of the two nanocarriers potentiated the decrease in ERalpha protein, 
concomitantly with decreasing tumour vasculature and glucose transporter-1. These data 
support that the targeted delivery of ERalpha-siRNA in breast tumors potentiates the 
inhibition of E(2)-induced proliferative activity by encapsulated AE through enhanced anti-
vascular activity. The study findings suggest that the anti-oestrogen activity of RU as well as 
that of targeted ERalpha-siRNA leads to anti-angiogenic activity. Their delivery in “stealth” 
nanocarriers may constitute a new anti-cancer therapeutic strategy in solid tumors. For 
example to create “stealth” (sneaky) characteristics for nanoparticles the surface of the 
particles were coated with polyethylene glycol (PEG), a procedure called PEGylation to 
protect nanocarriers from the reticulo-endothelial system.  
Tan et al (Tan et al., 2007) synthesized chitosan NPs with encapsulated quantum dots (QDs) 
to deliver HER2/neu siRNA. These constructs were tested for the delivery and track the 
siRNA by monitoring the presence of fluorescent QDs in the chitosan NPs. Chitosan is a 
linear polysaccharide compound composed of randomly distributed ┚-(1-4)-linked D-
glucosamine (deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit). It is a fiber 
isolated from shellfish. It has a unique property that allows it to bind with fat. Targeted 
delivery of HER2 siRNA to HER2-overexpressing SKBR3 breast cancer cells was shown to 
be specific with chitosan /QD NP surface labeled with HER2 antibody targeting the HER2 
receptors on SKBR3 cells. In this study gene-silencing effects of the conjugated siRNA was 
established using the luciferase and HER2 ELISA assays. These self-tracking siRNA delivery 
NPs could be useful in the monitoring of future gene silencing studies both in vitro and in 
vivo. 
3.4 Immunoconjugate linked NPs  
DeNardo et al studied (DeNardo et al., 2005) radioisotope conjugated-chimeric L6 mAb-
linked iron oxide nanoparticles (bioprobes) studied in athymic mice bearing human breast 
cancer HBT 3477 xenografts. These NP based bioprobes were given to i.v., escapes into the 
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extravascular space and bind to cancer cell membrane antigen, later these bioprobes can be 
used in concert with externally applied alternating magnetic field (AMF) to deliver 
thermoablative cancer therapy. The pharmacokinetics, tumor uptake, and the therapeutic 
effect of inductively heating by bioprobes indicated these probes were capable of killing 
breast cancer cells selectively. 
In another study Gao et al developed (Gao et al., 2009) PE38KDEL-loaded poly(lactic-co-
glycolic acid) (PLGA) nanoparticles conjugated to Fab' fragments of a humanized anti-HER2 
monoclonal antibody (rhuMAbHER2). The PE38KDEL-loaded nanoparticles-anti-HER2 Fab' 
bioconjugates (PE-NP-HER) were constructed modularly with Fab' fragments of 
rhuMAbHER2 covalently linked to PLGA nanoparticles containing PE38KDEL. Compared 
with nontargeted nanoparticles that lack anti-HER2 Fab', PE-NP-HER specifically bound to 
and were sequentially internalized into HER2 overexpressing breast cancer cells, which 
resulted in significant cytotoxicity in vitro.  
Recently Chattopadhyay et al reported (Chattopadhyay et al., 2010) an immunoconjugate 
linked 30nm AuNPs for HER-2 targeting NPs. This nanotechnology-based radiosensitizer 
was tested on SK-BR-3 breast cancer cells in vitro. This newly designed trastuzumab-AuNPs 
described in this study could be useful to for breast cancer treatment. 
4. Nanoparticles in clinical studies for breast cancer therapy  
Ranson et al, published the treatment outcome of Caelyx (Doxil; Sequus Pharmaceuticals 
Inc, Menlo Park, CA), the PEGylated liposomal doxorubicin NP in advanced breast cancer 
(Ranson et al., 1997). In advanced breast cancer, standard therapy regimens yield infrequent 
complete responses, and continued therapy has been associated with an improved quality of 
life (Coates et al., 1987) and favorable time to progression (Muss et al., 1991)  over 
intermittent therapy or observation, respectively.  This study reported median survival of 7 
months and the 9-month time to progression in the responding patients and it proposed if 
the majority of patients that completed six cycles had received additional Caelyx, the 
survival and time to progression might have been extended further. 
Metastatic breast cancer is still incurable. Taxanes represent an important class of antitumor 
agents, which have proven to be fundamental in the treatment of advanced and early-stage 
breast cancer, but the clinical advances of taxanes have been limited by their highly 
hydrophobic molecular status. To overcome this poor water solubility, lipid-based solvents 
have been used as a vehicle, and new systemic formulations have been developed, mostly 
for paclitaxel, which are Cremophor-free and increase the circulation time of the drug. ABI-
007 is a novel, albumin-bound, 130-nm particle formulation of paclitaxel, free from any kind 
of solvent. It has been demonstrated to be superior to an equitoxic dose of standard 
paclitaxel with a significantly lower incidence of toxicities in a large, international, 
randomized phase III trial. The availability of new drugs, such as Abraxane, in association 
with other traditional and non-traditional drugs (new antineoplastic agents and targeted 
molecules), will give the oncologist many different effective treatment options for patients in 
this setting (Miele et al., 2009). 
In another study metastatic breast cancer (MBC) phase II study evaluated the efficacy and 
safety of weekly administration of nanoparticles with albumin-bound paclitaxel as a first-
line treatment (Mirtsching et al.). The overall response rate (ORR) was 42.2% (95% CI, 30%-
55%); 5 patients had a complete response (CR) and 22 patients had a partial response (PR). 
Additionally, 17 patients experienced stable disease (SD), providing an overall benefit (CR + 
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PR + SD) of 68.8%. These findings demonstrated that weekly NP- paclitaxel had a favorable 
safety profile and is well tolerated as a first-line treatment for MBC. An ORR of 42% and an 
overall benefit of 69% is extremely encouraging, particularly in the HER2-positive 
population where 52% of patients responded. Clinically approved NP-conjugates for breast 
cancer are listed in Table 1.   
 
NP type /material 
(Brand Name) 
Drug entrapped or 
linked 
Current stage of 
development 
References 
PEG-liposomes 
(Doxil/Caelyx) 
Doxorubicin Phase I/II (Coates et al., 
1987; Ranson et 
al., 1997) 
Albumin (Abraxane) Paclitaxel Phase II/III (Lobo et al., 2007; 
Miele et al., 2009; 
Moreno-Aspitia & 
Perez, 2005) 
Table 1. Nanoparticles and their current stage of development for use in breast cancer 
therapy 
5. Summary 
In conclusion, we envision that breast cancer targeting agents such as miRNAs, siRNAs, and 
immunoconjugates are already demonstrated that these agents could be potential molecules 
for molecular cancer therapy. Only few siRNAs are in clinical trials because of their off-
target effects, and the efforts being made to develop miRNAs as either diagnostic or 
therapeutic markers, since these they are one of the natural mechanisms to control the gene 
expression. For example Rosetta Genomics, Israel-based microRNA Genomics Company is 
already actively planning for Investigational New drug (IND) study using miRNA for 
infectious disease and hepatocellular carcinoma the fifth most common cancer in the world. 
Similarly, the first in-human phase I clinical trial involving the systemic administration of 
siRNA to patients with solid cancers using a targeted, nanoparticle delivery system. Davis et 
al., (California Institute of Technology, Pasadena, California 91125, USA) study indicated the 
evidence of inducing an RNAi mechanism of action in a human from the delivered siRNA. 
Tumour biopsies from melanoma patients obtained after treatment show the presence of 
intracellularly localized nanoparticles in amounts that correlate with dose levels of the 
nanoparticles administered. 
Several reports have shown that use of nanoparticles and nanotechnologies have been 
giving very encouraging results.  One of the efficient ways to deliver these therapeutic 
molecules is through the use of nanoparticles. These novel technologies will help in 
achieving accurate early detection, prognosis, imaging and targeted therapy for breast 
cancer.   
In spite of many positive reports on this area, very few nanoparticles linked with targeting 
agents are showed desired properties for clinical studies. Further studies are needed in 
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translational research to incorporate these molecules into nanoparticles for the cancer 
treatment options. Therefore active research on nanotechnology warrants as answer for a 
number of questions prior to translational research: example specificity, toxicity, well 
defined characterization, stringent quality and in vivo clearance profile. Although active 
researches are ongoing in this area still we need to go a long way to achieve curable 
treatment outcome using these agents and technology. 
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